NO944934L - Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom - Google Patents

Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom

Info

Publication number
NO944934L
NO944934L NO944934A NO944934A NO944934L NO 944934 L NO944934 L NO 944934L NO 944934 A NO944934 A NO 944934A NO 944934 A NO944934 A NO 944934A NO 944934 L NO944934 L NO 944934L
Authority
NO
Norway
Prior art keywords
inhibition
post
vasomotor symptoms
psychological disorders
menopausal syndrome
Prior art date
Application number
NO944934A
Other languages
English (en)
Other versions
NO944934D0 (no
Inventor
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944934D0 publication Critical patent/NO944934D0/no
Publication of NO944934L publication Critical patent/NO944934L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anvendelse av en forbindelse med formelen OCH2CH2¿R2 R-O' (I) hvor R1 og R3 uavhengig av hverandre er hydrogen, O O -CH3, C-fCj-Cfc-alkyl ) eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldlno og plperldlno; eller et farmasøytisk akseptable salt eller solvat derav, l fremstillingen av et medikament som er nyttig for hemming av vasomotoriske symptomer og følgende psykologiske forstyrrelser l forbindelse med post-menopausalt syndrom.
NO944934A 1993-12-21 1994-12-19 Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom NO944934L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/173,502 US5534526A (en) 1993-12-21 1993-12-21 Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome

Publications (2)

Publication Number Publication Date
NO944934D0 NO944934D0 (no) 1994-12-19
NO944934L true NO944934L (no) 1995-06-22

Family

ID=22632322

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944934A NO944934L (no) 1993-12-21 1994-12-19 Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom

Country Status (15)

Country Link
US (1) US5534526A (no)
EP (1) EP0659415A3 (no)
JP (1) JPH07196500A (no)
KR (1) KR950016730A (no)
CN (1) CN1108093A (no)
AU (1) AU691844B2 (no)
CA (1) CA2138499A1 (no)
CZ (1) CZ320994A3 (no)
HU (1) HUT71478A (no)
IL (1) IL112038A0 (no)
NO (1) NO944934L (no)
NZ (1) NZ270168A (no)
PH (1) PH31327A (no)
RU (1) RU94045278A (no)
ZA (1) ZA9410093B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5512296A (en) * 1994-08-22 1996-04-30 Eli Lilly And Company Methods for inhibiting neuronal damage
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
HUP0101404A3 (en) * 1998-03-02 2002-09-30 Lilly Co Eli Fluoxetine hydrochloride for decreasing hot flashes
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
JP2002518329A (ja) 1998-06-16 2002-06-25 イーライ・リリー・アンド・カンパニー アセチルコリンレベルを増加させる方法
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
CZ20013912A3 (cs) 1999-05-04 2002-05-15 Strakan Limited Androgen glykosid, sloučenina, testosteron-ß-D-glukosid, 5 alfa-Dihydrotestosteron- 17ß-D-glukosid, farmaceutický prostředek a pouľití sloučeniny
RU2192639C1 (ru) * 2001-04-05 2002-11-10 Дальневосточный государственный медицинский университет Способ прогнозирования нарушений в постменопаузальном периоде
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
CN102223893B (zh) 2008-07-22 2014-07-16 曼诺吉尼克斯公司 治疗与绝经、激素改变和关节炎相关的症状的组合物和方法
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (no) * 1962-09-13
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome

Also Published As

Publication number Publication date
RU94045278A (ru) 1996-11-10
KR950016730A (ko) 1995-07-20
CA2138499A1 (en) 1995-06-22
ZA9410093B (en) 1996-06-19
CZ320994A3 (en) 1995-08-16
PH31327A (en) 1998-07-06
IL112038A0 (en) 1995-03-15
NZ270168A (en) 1997-07-27
AU8154894A (en) 1995-06-29
AU691844B2 (en) 1998-05-28
NO944934D0 (no) 1994-12-19
EP0659415A3 (en) 1995-10-11
HU9403662D0 (en) 1995-02-28
CN1108093A (zh) 1995-09-13
US5534526A (en) 1996-07-09
EP0659415A2 (en) 1995-06-28
HUT71478A (en) 1995-11-28
JPH07196500A (ja) 1995-08-01

Similar Documents

Publication Publication Date Title
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944930L (no) Hemming av dysfunksjonell uterin blödning
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
FI952014A0 (fi) Uusia bisyklisiä merkaptoasetyyliamidilaktaamijohdannaisia, jotka ovat hyödyllisiä enkefalinaasin ja ACE:n inhibiittoreina
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
EP0487502A3 (en) Pharmaceutically active aryl-substituted amine derivatives
ES8303291A1 (es) Un procedimiento para la preparacion de nuevos derivados de ariletanolamina.
NZ214787A (en) Arylcyclobutylalkylamines and pharmaceutical compositions
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
NO930783D0 (no) Kondenserte heterocykliske ketonderivater deres fremstilling og anveendelse
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
TW249804B (no)
NO944069L (no) Hemming av uterinfibrose
NO940788L (no) Benzoxazin-derivater, deres fremstilling og deres terapeutiske anvendelse
NO944923L (no) Hemming av vektökning eller indusering av vekttap
DK118083D0 (da) Theophyllinylalkyloxadiazoler eller additionssalte deraf, deres fremstilling og anvendelse som laegemidler
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
HUP0001827A2 (hu) Kolchicin-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények, és a vegyületek alkalmazása gyógyszerkészítmények előállítására
NO944577L (no) Hemming av effekten av amyloidogene proteiner